EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands

R Jajou iD, E P van Puijenbroek iD, K Hek iD, J A Overbeek iD, F P A M van Hunsel iD, Erik Mulder, A C Kant iD

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70317 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von R Jajou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. Hauptthemen laut MEDLINE: Venous Thromboembolism, Primary Health Care, COVID-19 Vaccines, Referral and Consultation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Welfare and Sport.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Venous thromboembolism (VTE) is labeled as an adverse effect of the adeno‐vector‐based vaccines AstraZeneca and Johnson & Johnson. We aimed to study whether there was an increase in general practitioner (GP) consultations for VTE after COVID‐19 vaccination.

Methods

An exposure‐anchored self‐controlled cohort study was performed among COVID‐19 vaccinated persons aged ≥ 12 years who were registered in the PHARMO Data Network and Nivel Primary Care Database in the Netherlands. The focal window was set at 28 days after each COVID‐19 vaccination and the referent window at all time outside the focal window. Adjusted incidence rate ratios (aIRR), adjusting for SARS‐CoV‐2 infection, were calculated using Poisson regression.

Results

In total, 2 133 853 persons were included. The highest increase in GP consultations for VTE was observed after Johnson & Johnson vaccination (aIRR: 3.14, 95% CI: 1.50–6.57), and a slight increase after Pfizer/BioNTech dose 1 (aIRR: 1.24, 95% CI: 1.09–1.40). Risk groups were 12–60 year‐olds with increased GP consultations for VTE after Johnson & Johnson (aIRR: 2.30, 95% CI: 1.44–3.69) and Pfizer/BioNTech (aIRR: 1.29, 95% CI: 1.11–1.50), and in specific groups of males aged 12–60 years. Also, females using hormone‐containing contraceptives or hormone replacement therapy (HRT) showed increased GP consultations for VTE after AstraZeneca (aIRR: 2.87, 95% CI: 1.13–7.33) and Pfizer/BioNTech (aIRR: 1.48, 95% CI: 1.10–2.01).

Conclusion

Increased GP consultations for VTE were observed after both vector and mRNA vaccination, in particular among males, 12–60 year olds, and females using hormone‐containing contraceptives or HRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismPrimary Health CareCOVID-19 VaccinesReferral and ConsultationCOVID-19General PractitionersHumansFemaleMaleNetherlandsMiddle AgedAdultAdolescentAgedCohort StudiesYoung AdultChildVaccinationBNT162 Vaccine

Stichwörter der Autor:innen

COVID‐19 vaccinationmRNA vaccinationprimary healthcare dataself‐controlled cohort studyvector vaccinationvenous thromboembolism

Substanzen

COVID-19 VaccinesBNT162 Vaccine

Autor:innen und Institutionen

  • Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.
  • Department of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, the Netherlands.
  • Nivel (Netherlands Institute for Health Services Research), Utrecht, the Netherlands.
  • PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: R Jajou, E P van Puijenbroek, K Hek, J A Overbeek, F P A M van Hunsel, A C Kant

Förderung

  • Ministry of Health, Welfare and Sport

Zitieren

APA

Jajou, R., van Puijenbroek, E. P., Hek, K., Overbeek, J. A., van Hunsel, F. P. A. M., Mulder, E., & Kant, A. C. (2026). GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70317

Vancouver

Jajou R, van Puijenbroek EP, Hek K, Overbeek JA, van Hunsel FPAM, Mulder E, et al. GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70317

BibTeX
@article{Jajou2026,
  author = {Jajou, R and van Puijenbroek, E P and Hek, K and Overbeek, J A and van Hunsel, F P A M and Mulder, Erik and Kant, A C},
  title = {GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70317}
}
Kostenlos starten →